Pharmacy - Emergency Medicine Deep Dive Podcast

When a cardiac arrest or trauma activation is called, most people think of physicians, nurses, and respiratory therapists. But what role does the emergency medicine pharmacist play when every second counts? In this episode, we explore the growing evidence behind pharmacists on resuscitation teams, from improving ACLS guideline adherence and reducing medication errors to helping deliver life-saving therapies more quickly. We also discuss what happens behind the scenes during a Code Blue, the specialized training that prepares pharmacists for these high-stakes situations, and the challenges that continue to limit their integration into emergency departments. Whether you're an emergency clinician, pharmacist, learner, or simply curious about how resuscitation teams work, this episode offers an evidence-based look at why pharmacists are becoming an increasingly important part of emergency care. As an emergency medicine pharmacist, this is a topic that is especially meaningful to me and I'm excited to share both the evidence and the real-world perspective behind it.

Restarting blood thinners after an intracranial hemorrhage is one of the most challenging decisions in neurology and stroke care. Restart too early and the risk of recurrent bleeding rises. Wait too long and patients may be left vulnerable to stroke or other thromboembolic complications. In this episode, we break down the latest evidence on when to resume antiplatelet and anticoagulant therapy, why recommendations differ for conditions such as mechanical heart valves and atrial fibrillation, and how factors like hemorrhage location and cerebral amyloid angiopathy shape decision making. We also explore how imaging findings and validated risk assessment tools can help individualize treatment for each patient. Whether you're a neurologist, emergency physician, internist, pharmacist, or trainee, you'll leave with practical, evidence-based strategies to navigate one of the most complex dilemmas in modern neurovascular care.

Your patient has a pulse again, but will your vasopressor choice determine whether they keep it? In this episode, we tackle one of the most common yet underappreciated decisions in post-cardiac arrest care: epinephrine or norepinephrine for post-ROSC hypotension. We break down the physiology of the stunned myocardium, explore why epinephrine may increase the risk of recurrent cardiac arrest, and examine the landmark trials and latest meta-analysis that are reshaping clinical practice. Most importantly, we translate the evidence into practical bedside recommendations you can apply on your very next shift. If you care for critically ill patients in the emergency department, ICU, or anywhere along the resuscitation continuum, this is an episode you won't want to miss.

Sepsis demands timely, effective antimicrobial therapy, but does how we administer beta-lactam antibiotics matter? In this episode, we take a deeper dive into the growing evidence behind prolonged beta-lactam infusion strategies and explore why recent guidelines now recommend extended or continuous infusions for many patients with sepsis and septic shock. We unpack the pharmacokinetic and pharmacodynamic principles, review key clinical trials and meta-analyses demonstrating improved outcomes, and discuss the critical role of an appropriate loading dose. We also examine which patient populations may benefit the most, including those with augmented renal clearance or altered physiology and when therapeutic drug monitoring should be considered. Finally, we tackle the practical challenges of implementing prolonged infusions in clinical practice, from drug stability and IV compatibility to the unanswered questions surrounding antimicrobial resistance.

Ketamine is best known for its roles in analgesia, sedation, and depression, but could it also help patients navigate the most challenging phase of opioid agonist therapy initiation in the fentanyl era? In this episode, we explore the emerging science behind ketamine as an adjunctive treatment for opioid withdrawal and OAT initiation, including its potential effects on NMDA receptors, opioid tolerance, and receptor signaling. We review the latest clinical evidence, from case reports of refractory withdrawal to early studies suggesting improved retention in treatment through rapid relief of depression and withdrawal distress. We'll also unpack the fascinating biology of beta-arrestin, receptor internalization, and whether ketamine may help improve opioid responsiveness by rebalancing some of the neurobiological changes associated with chronic fentanyl exposure. Join us as we separate promise from proof and discuss where ketamine may fit and where it may not in the future of addiction care.

In this episode, we explore the race against time in trauma care and why every minute matters when treating life-threatening bleeding. Drawing on evidence from major clinical trials and meta-analyses, we examine how tranexamic acid (TXA) can dramatically improve survival when administered as early as possible after injury. You'll learn why the greatest benefits occur within the first hour, why effectiveness begins to decline after 90 minutes, and how even short delays can significantly reduce a patient's chance of survival. We also discuss emerging evidence suggesting that rapid treatment may be more important than where the treatment is delivered. Whether you're a healthcare professional, student, or simply interested in emergency medicine, this episode highlights how timely intervention can save lives in trauma, hemorrhagic shock, and traumatic brain injury.

How low should you go when lowering blood pressure in acute intracerebral hemorrhage, and can treating too aggressively actually cause harm? In this episode, we explore the pathophysiology of ICH, including why spontaneous hemorrhage lacks a true ischemic penumbra and how perihematomal benign oligemia supports the safety of blood pressure reduction. We review the landmark INTERACT-2 and ATACH-II trials, along with the newer INTERACT-3 and INTERACT-4 studies, to uncover how the evidence has shaped modern practice and reinforced the lesson that lower is not always better. We discuss current guideline recommendations, including the shift toward a systolic blood pressure target of 130 to 150 mmHg and the importance of minimizing blood pressure variability. Finally, we compare commonly used agents such as nicardipine and clevidipine and revisit the longstanding controversy surrounding hydralazine and its purported effects on intracranial pressure and hematoma expansion.

In toxicology-induced status epilepticus, the clock starts ticking the moment first-line benzodiazepines fail. In this episode, we dive into the evolving evidence behind second-line therapies for benzodiazepine-refractory seizures, exploring why phenobarbital remains the best-supported option based on pharmacologic principles and animal data, while propofol emerges as a powerful rescue therapy in intubated patients. We also unpack the growing interest in levetiracetam, a medication praised for its favorable safety profile and minimal cardiorespiratory effects, but whose effectiveness in toxicologic seizures remains uncertain, particularly in stimulant-related cases highlighted by the ESETT subgroup analysis. Along the way, we examine why older agents like phenytoin may have little to no role in poisoned patients despite their historic use in seizure management. Through real-world clinical dilemmas, pharmacology insights, and emerging research, we explore how emergency clinicians navigate the race to stop seizures before irreversible neurological injury occurs. Whether you’re passionate about emergency medicine, toxicology, critical care, or neuropharmacology, this episode delivers a fascinating look at one of medicine’s highest-stakes treatment decisions.

Stroke thrombolysis is rapidly evolving and tenecteplase is emerging as one of the most exciting developments in acute ischemic stroke care. In this episode, we explore how a simple change from a one-hour infusion to a single IV bolus could transform stroke treatment workflows, improve transfer logistics, and potentially enhance early reperfusion in some patients. We unpack the science behind tenecteplase, review the landmark trials that challenged alteplase’s decades-long dominance, and discuss why clinicians around the world are paying close attention. From breakthrough studies in large vessel occlusion to major safety and non-inferiority trials, this episode highlights the evidence shaping modern stroke practice. This episode offers a practical and engaging overview of one of the biggest shifts in contemporary stroke care.

In this episode, we dive into the evolving evidence behind proton pump inhibitors (PPIs) in the management of nonvariceal upper gastrointestinal bleeding. While PPIs have long been considered standard early therapy, emerging data challenge whether starting treatment before endoscopy meaningfully improves major clinical outcomes such as mortality, surgery, or overall rebleeding rates. We explore how current evidence suggests the clearest benefit may be in patients with confirmed peptic ulcer bleeding, where PPIs can help reduce recurrent bleeding after endoscopic therapy. The episode also examines the growing shift away from continuous IV infusions toward intermittent dosing strategies, which appear similarly effective while potentially reducing cost and resource use. Join us as we unpack how evidence-based medicine is reshaping long-standing practices in emergency gastrointestinal care.